Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia

Lasalvia, Pieralessandro

Hernández, Fabián

Castañeda-Cardona, Camilo

Cuestas, Andrés

Rosselli, Diego

Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/